Radium-223 Plus Sipuleucel-T Yields Mixed Results in mCRPC

Radium-223 Plus Sipuleucel-T Yields Mixed Results in mCRPC: Combination therapy with radium-223 and sipuleucel-T yielded conflicting results in patients with metastatic castration-resistant prostate cancer.

Comments

Popular posts from this blog

A 10-Second Steam Blast: The New Weapon Against Prostate Cancer?

Researchers develop low-cost device that detects cancer in an hour | ScienceDaily

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News